Preclinical studies demonstrating that the FDA-approved ALK inhibitor, crizotinib, also inhibits ROS1 provided rationale for its use in treatment of ROS1+ NSCLC patients [28]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.